Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362176 · ClinicalTrials.gov registry record · Phase 3
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 974
- Enrollment target
NCT04362176 is a Phase 3 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 974 participants.
The verdict
NCT04362176, a Phase 3 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 974 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID-19 7-point Ordinal Clinical Progression Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL pathogen reduced SARS-CoV-2 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 974 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2021-08-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362176
The ClinicalTrials.gov registry entry for NCT04362176 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 974 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04362176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362176 about?
NCT04362176 is a clinical study titled "Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults". The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID-19 7-point Ordi...
What is the current status of trial NCT04362176?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 974 participants. The study started on 2020-04-24. Estimated completion is 2021-08-06.
What interventions are being tested in trial NCT04362176?
The interventions under investigation include: Placebo (BIOLOGICAL), pathogen reduced SARS-CoV-2 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04362176?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.